Anest. intenziv. Med. 2008;19(5):269-278

Immunopathogenenis of sepsisIntesive Care Medicine - Review Article

Průcha Miroslav1,*, Fedora Michal2
1 Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha
2 Klinika dětské anesteziologie a resuscitace LF MU a Fakultní nemocnice Brno

Sepsis represents a major unresolved problem of current medicine. The important characteristic of sepsis is the interaction between the two subjects - the macro and the microorganism. The concept of a hyperinflammatory syndrome, dominant for two decades, has been challenged and our current understanding is that sepsis represents a dynamic syndrome characterized by many often antagonistic phenomena. Inflammation which characterizes sepsis does not act as a primary physiological compensatory mechanism but rather oscillates between the phases of a hyperinflammatory response and anergy or immunoparalysis. Understanding the pathogenesis of sepsis means understanding the immunopathological processes that characterize the interaction between the macro and the microorganism. The characteristics of the macroorganism - the genetic predisposition, the role of the innate and adaptive immunity systems, the "high" or "low" host response concerning the intensity of inflammation - form one side of the coin. The role of the microorganism is also important. The different ability of the species to produce pro- and antiinflammatory cytokines, their role in the innate immunity system and their different ability to escape the surveillance of the immune system form the second part in the pathogenesis of sepsis. The outcome of a patient is therefore the result of a very heterogenous and dynamic set of interactions and these complicated interactions have not been fully elucidated and understood yet.

Keywords: sepsis; macroorganism; microorganism; inflammation; innate immunity; immunoparalysis; apoptosis

Received: May 14, 2008; Accepted: August 20, 2008; Published: October 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Průcha M, Michal F. Immunopathogenenis of sepsis. Anest. intenziv. Med. 2008;19(5):269-278.
Download citation

References

  1. Martin, G. S., Mannino, D. M., Eaton, S., Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. England J. M., 2003, 348, p. 1546-1554. Go to original source... Go to PubMed...
  2. Černý, V., Novák, I., Šrámek, V. Prevalence těžké sepse v České republice - prospektivní multicentrická jednodenní studie. Anest. intenziv. Med., 2003, 14, p. 218-222.
  3. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J. et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med., 2001, 29, p. 1303-1310. Go to original source... Go to PubMed...
  4. Dombrovskiy, V. Y., Martin, A. A., Sunderram, J. et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit. Care Med., 2007, 35, p. 1244-1250. Go to original source... Go to PubMed...
  5. Dellinger, R. P. Cardiovascular management of septic shock. Crit. Care Med., 2003, 31, 3, p. 946-955. Go to original source... Go to PubMed...
  6. Esper, A., Martin, G. S. Is severe sepsis increasing in incidence AND severity? Crit. Care Med., 2007, 35, 5, p. 1414-1415. Go to original source... Go to PubMed...
  7. Bone, R. C., Balk, R. A.,Cerra, F. B. et al. American College of Chest Physicians/Society of Critical Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of Innovative therapies in sepsis. Chest, 1992, 101, p. 1644-1655. Go to original source... Go to PubMed...
  8. Levy, M. M., Fink, M. P., Marshall, J. C. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med., 2003, 29, p. 530-538. Go to original source... Go to PubMed...
  9. Calandra, T., Baumgartner, J. D., Grau, G. et al. Prognostic value of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J. Infect. Dis., 1990, 161, p. 982-987. Go to original source... Go to PubMed...
  10. Cassatella, M. A., Meda, L., Bonora, S. et al. Interleukin-10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med., 1993, 178, p. 2207-2211. Go to original source... Go to PubMed...
  11. Damas, P., Reuter, A., Gysen, P. et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med., 1989, 17, p. 975-978. Go to original source... Go to PubMed...
  12. Emery, P., Salmon, M. The immune response: systemic mediators of inflammation. Br. J. Hosp. Med., 1991, 45, 1, p. 64-168.
  13. Abbas, A. K., Murphy, K. M., Sher, A. Functional diversity of helper T lymphocytes. Nature, 1996, 383, p. 787-793. Go to original source... Go to PubMed...
  14. Borowikova, L. V., Ivanova, S., Zhang, H. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 2000, 405, p. 458-462. Go to original source... Go to PubMed...
  15. Woiciechowsky, C., Asadullah, K., Nestler, D. et al. Sympathetic activation triggers systemic IL-10 release in immunodepression induced by brain injury. Nat. Med., 1998, 4, p. 808-813. Go to original source... Go to PubMed...
  16. Heidecke, C. D., Hensler, T., Weighradt, H. et al. Selective defects of T lymphocytes function in patiens with lethal intraabdominal infection. Am. J. Surg., 1999, 178, p. 288-292. Go to original source... Go to PubMed...
  17. Pellegrini, J. D., De Ak, J., Kodys, K. et al. Relationships between T lymphocytes apoptosis and anergy following trauma. J. Surg. Res., 2000, 88, p. 200-206. Go to original source... Go to PubMed...
  18. Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E. et al. Sepsis-induced apoptosis cause progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol., 2001, 166, p. 6952-6963. Go to original source... Go to PubMed...
  19. Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E. et al. Depletion of dendritic cells, but not macrophages, in patiens with sepsis. J. Immunol., 2002, 168, p. 2493-2500. Go to original source... Go to PubMed...
  20. Fukuzuka, K., Edwards, C. K., Clare-Walter, M. et al. Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 278, p. R1005-1018. Go to original source... Go to PubMed...
  21. Greene, D. R., Beere, H. M. Apoptosis:gone but not forgotten. Nature, 2000, 405, p. 28-29. Go to original source... Go to PubMed...
  22. Fadok, V. A., Bratton, D. L., Rose, D. M. et al. A receptor for phosphatidylserine-specific clearence of apoptotic cells. Nature, 2000, 405, p. 85. Go to original source... Go to PubMed...
  23. Eichacker, P. Q., Parent, C., Kalil, A. et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med., 2002, 166, p. 1197-205. Go to original source... Go to PubMed...
  24. Macias, W. L., Nelson, D. R., Wiliams, M. et al. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit. Care, 2005, 9, R607-622. Go to original source... Go to PubMed...
  25. Marshall, J. C. The staging of sepsis: understanding heterogeneity in treatment efficacy. Crit. Care, 2005, 9, p. 626-628. Go to original source... Go to PubMed...
  26. Průcha, M., Herold, I., Zazula, R., Dubská, L., Kavka, B. Monocytární deaktivace a produkce tumor nekrotizujícího faktoru-α ex vivo - prognostické parametry u pacientů jednotek intenzivní péče. Anest. intenziv. Med., 2003, 5, p. 223-228.
  27. Calandra, T., Echtenacher, B., Le Roy, D. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine, 2000, 6, p. 164-170. Go to original source... Go to PubMed...
  28. Wang, H., Zhang, M. et al. HMG-I as a late mediator of endotoxin letality in mice. Science, 1999, 285, p. 248-251. Go to original source... Go to PubMed...
  29. Tschaikowsky, K., Geissing, M. H., Schiele, A. et al. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen - DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit. Care Med., 2002, 30, p. 1015-1023. Go to original source... Go to PubMed...
  30. Oberholzer, A., Sousa, S. M., Tschoeke, S. K. et al. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock, 2005, 23, p. 488-493. Go to PubMed...
  31. Groeneveld, A. B. J., Bossink, A. W. J., Mierlo, G. J., Hack, C. E. Circulating inflammatory mediators in patients with fever: predicting bloodstream infection. Clin. Diagn. Lab. Immunology, 2001, 8, p. 1189-1195. Go to original source... Go to PubMed...
  32. D'Andrea, A., Aste-Amezaga, M., Valiante, N. M. et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by supressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med., 1993, 178, p. 1041-1048. Go to original source... Go to PubMed...
  33. De Vries, J. E., de Waal Malefyt K. Immunosuppressive and anti-inflammatory effects of human interleukin-10. In Faits, E., Baue, A. E., Schildberg, F. W. (Eds.) The immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches 1996. Pabst Science Publishers, p. 303-307. Go to original source...
  34. Oberholzer, A., Oberholzer, C., Moldawer, L. L. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit. Care Med., 2002, 30, S58-S63. Go to original source...
  35. Janeway, C. A., Bottomly, K., Babich, J. Quantitative variation in Ia antigen expression plays a central role in immune regulation. Immunol. Today, 1984, 5, p. 99-105. Go to original source... Go to PubMed...
  36. Docke, W. D., Syrbe, U., Meinecke, A. et al. Improvement of monocyte function - a new therapeutic approach? Update to Intensive Care and Emergency Medicine, 1994, 18, p. 473-500. Go to original source...
  37. Rothe, G., Oser, A., Valet, G. Dihydrorhodamin 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften, 1988, 73, p. 354-356. Go to original source... Go to PubMed...
  38. Platzer, C., Richter, G., Uberla, K. et al. Analysis of cytokine mRNA levels in interleukin-4 transgenic mice by quantitative polymerase chain reaction. Eur. J. Immunol., 1992, 22, p. 1179-1184. Go to original source... Go to PubMed...
  39. Munoz, C., Carlet, J., Fitting, C. et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest., 1991, 88, p. 1747-1754. Go to original source... Go to PubMed...
  40. Abraham, E. Physiologic stress and cellular ischemia: Relationship immunosuppression and susceptibility to infection. Crit. Care Med., 1991, 19, p. 613-618. Go to original source... Go to PubMed...
  41. Dinarello, C. A. The proinflammatory cytokine interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis., 1991, 163, p. 1177-1184. Go to original source... Go to PubMed...
  42. Doughty, L., Patrene, K., Boggs, S. et al. Supression of native IL-10 production by constitutive expression of viral IL-10 (vIL-10) or soluble TNF receptor p75 (sTNFR) in mice. Abstr. Crit. Care Med., 1996, 24 (Suppl): A32.
  43. Hamilton, G., Hofbauer, S., Hamilton, B. Endotoxin, TNF-α, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand. J. Infect. Dis., 1992, 24, p. 361-368. Go to original source... Go to PubMed...
  44. Cheadle, W. G., Hershman, M. J., Wellhausen, S. R. et al. Role of monocytic HLA-DR expression following trauma in predicting clinical outcome. In Faist, E., Ninnemann, J., Green, D. (Eds) Immune Consequences of Trauma, Shock and Sepsis. Springer-Verlag : Berlin, Heidelberg, New York 1989, p. 199-222. Go to original source...
  45. De Waal Malefyt, K., Haanen, J., Spits, H. et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med., 1991, 174, p. 915-924. Go to original source... Go to PubMed...
  46. Durez, P., Abramowicz, D., Gerard, C. et al. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin. J. Exp. Med., 1993, 177, p. 551-555. Go to original source... Go to PubMed...
  47. D'Andrea, A., Aste-Amezaga, M., Valiante, N. M. et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by supressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med., 1993, 178, p. 1041-1048. Go to original source... Go to PubMed...
  48. De Vries, J. E., de Waal Malefyt, K. Immunosuppressive and anti-inflammatory effects of human interleukin-10. In Faits, E., Baue, A. E., Schildberg, F. W. (Eds.) The immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches 1996. Pabst Science Publishers, p. 303-307. Go to original source...
  49. Chandry, D., Turner, M., Abney, A. et al. Modulation of cytokine production by transforming growth factor β. J. Immunol., 1989, 140, p. 4217-4222. Go to original source...
  50. Espenik, T., Figari, I. S., Shalaby, M. R. et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J. Exp. Med., 1987, 166, p. 571-576. Go to original source... Go to PubMed...
  51. Czarniecki, C. W., Chiu, H. H., Wong, G. H.W. et al. Transforming growth factor β modulates the expression of class II histocompatibility antigens on human cells. J. Immunol., 1988, 140, p. 4217-4222. Go to original source... Go to PubMed...
  52. Oczenski, W., Krenn, H., Jilch, R. et al. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med., 2003, dx.doi.org/10.1007/s00134-003-1826-8. Go to original source...
  53. Perry, S. E., Modrala, S. M., Wenstone, R. et al. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med., 2003, dx.doi.org/10.1007/s00134-003-1686-2. Go to original source...
  54. Braude, A. E., Jones, J. L., Douglas, H. The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. J. Immunol., 1963, 90, p. 297-301. Go to original source... Go to PubMed...
  55. Andriole, V. T. Urinary tract infections in the 90s: Pathogenesis and management. Infection, 1992, 20 (suppl. 4), S251-S256 Go to original source... Go to PubMed...
  56. Feltis, B. A., Jechorek, R. P., Erlanden, S. L. et al. Bacterial translocation and lipopolysaccharide-induced mortality in genetically macrophage-deficient op/op mice. Shock, 1994, 2, p. 29-33. Go to original source... Go to PubMed...
  57. Go, L. L., Healey, P. J., Watkins, S. C. et al. The effect of endotoxin on intestinal mucosal permeability to bacteria in vitro. Arch. Surg., 1995, 130, p. 53-58. Go to original source... Go to PubMed...
  58. Sedman, P. C., MacFie, J., Sagar, P. et al. The prevalence of gut translocation in humans. Gastroenterology, 1994, 107, p. 643-649. Go to original source... Go to PubMed...
  59. Cabie, A., Farkas, J. C., Fitting, C. et al. High levels of portal TNF-α during abdominal aortic surgery in man. Cytokine, 1993, 5, p. 448-453. Go to original source... Go to PubMed...
  60. Owens, W. E., Berg, R. D. Bacterial translocation from the gastrointestinal tract of thymectomized mice. Curr. Microbiol., 1982, 7, p. 169-174. Go to original source...
  61. O'Boyle, C. J., Mac Fie, J., Mitchell, C. J. et al. Microbiology of bacterial translocation in humans. Gut, 1998, 42, p. 29-35. Go to original source... Go to PubMed...
  62. Morin, M., Schindler, R., Wakabayashi, G. et al. Picogram concentrations of endotoxin stimulate synthesis of IL-1b and TNF-α by human peripheral blood mononuclear cells exposed to recombinant human C5a. Eur. Cytokine Netw., 1991, 2, p. 27-30. Go to PubMed...
  63. Quereshi, S. T., Lariviere, G., Leveque, S. et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4. J. Exp. Med., 1999, 189, p. 615-625. Go to original source... Go to PubMed...
  64. Cleveland, M. G., Gorham, J. D., Murphy, T. L. et al. Lipoteichoic acid preparations of Gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect. Immun., 1996, 64, p. 1906-1912. Go to original source... Go to PubMed...
  65. Nwariaku, F., Sikes, P., Lightfoot, E. et al. Role of CD14 in hemorrhagic shock-induced alterations of the monocyte tumor necrosis factor response to endotoxin. J. Trauma, 1996, 40, p. 564-567. Go to original source... Go to PubMed...
  66. Medzhitov, R., Janeway, C. Innate immunity: the virtues of a nonclonal system of recognition. Cell, 1997, 91, p. 295-298. Go to original source... Go to PubMed...
  67. Hemmi, H. A Toll-like receptor recognizes bacterial DNA. Nature, 2000, 408, p. 740-745. Go to original source... Go to PubMed...
  68. Ozinsky, A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA, 2000, 97, p. 13766-13771. Go to original source... Go to PubMed...
  69. Wiel, E., Lebuffe, G., Vallet, B. Bacterial CpG DNA in septic shock. In Vincent, J. L. (Ed.) Yearbook of Intensive Care and Emergency Medicine. 2002, p. 388-398. Go to original source... Go to PubMed...
  70. Schouten, M., Wiersinga, W. J., Levi, M., van der Poll Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol., 2008, 83, p. 536-545. Go to original source... Go to PubMed...
  71. Stief, T. W., Ijagha, O., Weiste, B. et al. Analysis of hemostasis alterations in sepsis. Blood Coagul. Fibrinolysis, 2007, 18, p. 179-186. Go to original source... Go to PubMed...
  72. Cohen, J., Cristofaro, P., Carlet, J., Opal, S. New method of classifying infections in critically ill patients. Crit. Care Med., 2004, 32, p. 1510-1526. Go to original source... Go to PubMed...
  73. Warris, A., Verweij, P. E., Gaustad, P. et al. Various Filamentous fungi digger in thein ability to induce TNF-α and IL-6 release in human monocyte culture. Agents Chemother., 2000, 40, p. 373-375.
  74. Opal, S. M., Gerber, G. E., La Rosa, S. P. et al. Systemic host response in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin. Infect. Diseases, 2003, 37, p. 50-58. Go to original source... Go to PubMed...
  75. Damas, P., Reuter, A., Gysen, P. et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med., 1989, 17, p. 975-978. Go to original source... Go to PubMed...
  76. Borrelli, E. et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit. Care Med., 1996, 24, p. 392-397. Go to original source... Go to PubMed...
  77. Dadák, L., Šťouračová, M., Štětka, P. et al. Rozšířený imunologický profil v prvních dnech pobytu a prognóza nemocných dlouhodobě hospitalizovaných na JIP. Anest. intenziv. Med., 2007, 3, s. 164-170.
  78. Abraham, E., Laterre, P. F., Garbino, J. et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double blind, placebo-controlled multicenter phase III trial with 1 342 patients. Crit. Care Med., 2001, 29, p. 503-510. Go to original source... Go to PubMed...
  79. Fisher, C. J. Jr et al. Treatment of septic shock with the tumor necrosis factor receptor-fusion protein. N. Engl. J. Med., 1996, 334, p. 1697-1702. Go to original source... Go to PubMed...
  80. Echtenacher, B., Urbaschek, R., Weigl, K. et al. Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology, 2003, 208, p. 381-389. Go to original source... Go to PubMed...
  81. Remick, D. G., Bolgos, G., Copeland, S., Siddiqui, J. Role of interleukin 6 in mortality from a physiological response to sepsis. Infection and Immunity, 2005, 73, p. 2751-2757. Go to original source... Go to PubMed...
  82. Bianchi, M. E. DAMPS, PAMPs and alarmins: all we need to know about danger. J. Leuko. Biology, 2007, 81, p. 1-5. Go to original source... Go to PubMed...
  83. Wiersinga, W. J., van der Poll, T. The Role of Toll-like Receptors in Sepsis. In Yearbook of Intensive and emergency medicine. Springer : Berlin, Heidelberg 2006, p. 3-13. Go to original source...
  84. Poltorak, A., He, X., Smirnova, I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScR mice: Mutation in TLR4 gene. Science, 1998, 282, p. 2085-2088. Go to original source... Go to PubMed...
  85. Beutler, B. Science review: key inflammatory and stress pathways in critical illness - the central role of the Toll-like receptors. Crit. Care, 2003, 7, p. 39-46. Go to original source...
  86. Smirnova, I., Mann, N., Dols, A. et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl. Acad. Sci. USA, 2003, 100, p. 6075-680. Go to original source... Go to PubMed...
  87. Ayala, A., Lomas, J. L., Grutkoski, P. S., Chung, C. S. Pathological aspects of apoptosis in severe sepsis and shock? Int. J. Biochem. & Cell Biol., 2003, 35, p. 715-720. Go to original source... Go to PubMed...
  88. Chung, C. S., Chaudry, I. H., Ayala, A. The apoptotic response of the lymphoid immune system to trauma, shock and sepsis. In Vincent, J. L. (editor) Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag : Berlin 2000. p. 27-40. Go to original source...
  89. Hotchkiss, R. S., Swanson, P. E., Freeman, B. D., Tinsley, K. W., Cobb, J. P., Matuschak, G. M. et al. Apoptotic cell death in patients with sepsis, shock and multiple organ dysfunction. Crit. Care Med., 1999, 27, p. 1230-1251. Go to original source... Go to PubMed...
  90. Hotchkiss, R. S., Swanson, P. E., Knudson, C. M., Chang, M. et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol., 1999, 162, p. 4148-4156. Go to original source... Go to PubMed...
  91. Vol, R. E., Hermann, M., Roth, E. A. et al. Immunosuppressive effects of apoptotic cells. Nature, 1997, 390, p. 350. Go to original source... Go to PubMed...
  92. Fadok, V. A., Bratton, D. L., Rose, D. M. et al. A receptor for phosphatidy serine-specific clearence of apoptotic cells. Nature, 2000, 405, p. 485-490. Go to original source... Go to PubMed...
  93. Braun, J. S., Novak, R., Herzog, K. H. et al. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med., 1999, 5, p. 298. Go to original source... Go to PubMed...
  94. Chung, C. H. S., Ying, X. X., Wang, W., Ayala, A. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch. Surg., 1998, 133, p. 1213-11215. Go to original source... Go to PubMed...
  95. Hotchkiss, R. S., Swanson, P. E., Freeman, B. D. et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA, 1999, 96, p. 14541-14546. Go to original source... Go to PubMed...
  96. Giamarellos-Bourboulis, E. J., Routsi, Ch., Plachouras, D. et al. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Critical Care, 2006, 10R76 (doi 10.1186/cc4921). Go to original source... Go to PubMed...
  97. Wesche-Soldato, D. E., Stan, R. Z., Chung, Ch. S., Ayala, A. The apoptotic pathway as a therapeutic target in sepsis. Curr. Drug Targets, 2007, 8, p. 493-500. Go to original source... Go to PubMed...
  98. Tang, A. H., Brunn, G. J., Cascalho, M., Platt, J. L. Pivotal advance: endogenous pathway to SIRS, sepsis, and related conditions. J. Leukoc. Biol., 2007, 82, p. 282-285. Go to original source... Go to PubMed...
  99. Liu, D., Lu, F., Qin. G. et al. C1 inhibitor-mediated protection from sepsis. J. Immunol., 2007, 179, p. 3966-3972. Go to original source... Go to PubMed...
  100. Guo, R. F., Ward, P. A. C5a, a therapeutic target in sepsis. Recent Patents Anti-Infect. Drug Disc., 2006, 1, p. 57-65. Go to original source... Go to PubMed...
  101. Werdan, K. Immunoglobulin treatment in sepsis - is the answer "no"? Crit. Care Med., 2006, 34, p. 1542-1544. Go to original source... Go to PubMed...
  102. Ishii, K. J., Uematsu, S., Akira, S. Toll Gates for future immunotherapy. Curr. Pharm. Des., 2006, 120, p. 4135-4142. Go to original source... Go to PubMed...
  103. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., Panoskaltsis, N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med., 2006, 355, 10, p. 1018-1028. Go to original source... Go to PubMed...
  104. Nierhaus, A., Montag, B., Timmler, N. et al. Reversal of immunoparalysis by recombinant human granulocyte - macrophage colony stimulating factor in patients with severe sepsis. Intensive Care Med., 2003, (on-line, Springer-Verlag 2003, 10.1007/s00134-003-1666-6). Go to original source... Go to PubMed...
  105. Flohe, S. B., Agrawal, H., Flohe, S. et al. Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol. Med., 2008, Feb 24 [Epub ahead of print]. Go to original source... Go to PubMed...
  106. Eichacker, P. Q., Natanson, C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med., 2007; 33 p. 396-399. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.